Molex’s subsidiary Phillips-Medisize has unveiled plans to build a new 80,000ft² manufacturing facility at its Menomonie, Wisconsin campus in the US.
The facility will be used to produce high volume prefilled drug delivery systems.
It is anticipated to employ over 100 people at full production. The facility is being developed to support Phillips-Medisize’s new supply contract with a biopharmaceutical firm.
Earlier this year, Phillips-Medisize opened a 17,000ft² clinical and pilot build facility for drug delivery and combination devices in Menomonie.
The company also expanded its New Richmond’s medical device facility in last November, and its Finland facility in late 2014.
Phillips-Medisize CEO and president Matt Jennings said: “This expansion illustrates our continued commitment and investment in the design and manufacturing of drug delivery devices for biopharmaceutical companies, globally.
“Expanding in Menomonie adds to our manufacturing capacity to produce fully assembled and packaged drug delivery devices.
“We are proud of this leading-edge manufacturing campus featuring advanced molding and assembly, cold-chain drug handling, serialization technologies and FDA-registered dedicated clinical and pilot build facilities for drug delivery and finished combination products.
In June this year, Phillips-Medisize acquired Medicom Innovation Partner, which is engaged in the design and development of connected health drug delivery systems and combination devices.
Phillips-Medisize is investing in its people via a collaboration with the University of Wisconsin-Stout, situated in Menomonie. It offers technical resources and an educated work force to meet the increasing demand of the drug delivery industry.
Image: Phillips-Medisize to build new facility to produce high volume prefilled drug delivery systems. Photo: courtesy of Baitong333 / FreeDigitalPhotos.net.